Second Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock
March 26 2021 - 5:00PM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the
"Company" or “Second Sight”), a leading developer and marketer of
implantable visual prosthetics that are intended to create an
artificial form of useful vision for blind individuals, today
announced that it has closed its previously announced private
placement, which resulted in gross proceeds to Second Sight of
$27.9 million, before deducting offering expenses. The net proceeds
from the private placement are expected to provide working capital
for the Company.
ThinkEquity, a division of Fordham Financial Management, Inc.,
acted as sole placement agent for the private placement
offering.
The securities offered and sold by Second Sight in the private
placement have not been registered under the Securities Act of
1933, as amended (the "Securities Act"), or state securities laws
and may not be offered or sold in the United States absent
registration with the Securities and Exchange Commission (the
"SEC") or an applicable exemption from such registration
requirements. Second Sight has agreed to file a registration
statement with the SEC covering the resale of the shares of common
stock to be issued in the private placement. Any resale of Second
Sight's shares under such resale registration statement will be
made only by means of a prospectus.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. The shares of common stock will not be registered
under the Securities Act or any state securities laws, and unless
so registered, may not be offered or sold in the United States
except pursuant to an exemption from the registration requirements
of the Securities Act and applicable state laws.
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops and
markets implantable visual prosthetics that are intended to deliver
useful artificial vision to blind individuals. A recognized global
leader in neuromodulation devices for blindness, the Company is
committed to developing new technologies to treat the broadest
population of sight-impaired individuals. The Company’s
headquarters are in Los Angeles, California. More information is
available at https://secondsight.com.
Safe Harbor
This press release contains certain “forward-looking statements”
within the meaning of the “safe harbor” provisions of the US
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “target,” “believe,”
“expect,” “will,” “may,” “anticipate,” “estimate,” “would,”
“positioned,” “future,” and other similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. Examples of forward-looking statements include,
among others, statements made in this press release regarding the
use of proceeds from the private placement. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on Second Sight’s current
beliefs, expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Actual results and outcomes may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause actual results and outcomes to differ
materially from those indicated in the forward-looking statements
include, among others, the following: (1) legal claims or
proceedings, if any, relating to Second Sight’s Memorandum of
Understanding with Pixium Vision and costs relating thereto; (2)
changes in applicable laws or regulations; (3) the possibility that
Second Sight may be adversely affected by other economic, business,
and/or competitive factors; (4) the impact of COVID-19 on Second
Sight’s business; and (5) other risks and uncertainties indicated
from time to time in Second Sight’s Form 10-K for the year ended
December 31, 2020, including those under “Risk Factors” therein,
and in Second Sight’s other filings with the SEC. Some of these
risks and uncertainties may in the future be amplified by the
COVID-19 outbreak and there may be additional risks that Second
Sight considers immaterial or which are unknown. A further list and
description of risks and uncertainties can be found in Second
Sight’s Annual Report on Form 10-K, filed on March 16, 2021. Any
forward-looking statement made by us in this press release is based
only on information currently available to Second Sight and speaks
only as of the date on which it is made. Second Sight undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210326005459/en/
Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793 E: lwilson@insitecony.com
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024